Condition: Moderate to Severe Plaque Psoriasis · Sponsor: UCB Biopharma SRL
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
This description comes directly from the study's public registry record.
UCB Cares · 1-844-599-2273 (USA) · ucbcares@ucb.com
UCB Cares · 001 844 599 2273 · UCBCares@ucb.com
Always discuss trial participation with your own doctor first.
| Ps0021 50162 | Fountain Valley, California, United States | Active Not Recruiting |
| Ps0021 50161 | Los Angeles, California, United States | Active Not Recruiting |
| Ps0021 50196 | Northridge, California, United States | Completed |
| Ps0021 50581 | Miami, Florida, United States | Withdrawn |
| Ps0021 50344 | Indianapolis, Indiana, United States | Active Not Recruiting |
| Ps0021 50599 | Kew Gardens, New York, United States | Withdrawn |
| Ps0021 50084 | Charleston, South Carolina, United States | Active Not Recruiting |
| Ps0021 50201 | Arlington, Texas, United States | Completed |
| Ps0021 50355 | Dallas, Texas, United States | Active Not Recruiting |
| Ps0021 40121 | Brussels, Belgium | Active Not Recruiting |
| Ps0021 40420 | Liège, Belgium | Withdrawn |
| Ps0021 50618 | Mississauga, Canada | Active Not Recruiting |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06425549